Status:
COMPLETED
Phase IIA Study in Patients With Schizophrenia
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study is designed to assess the effects of AZD 2624 in patients with schizophrenia
Eligibility Criteria
Inclusion
- Females of non-childbearing potential
- Diagnosis of Schizophrenia
Exclusion
- Clinically relevant disease and /or abnormalities.
- Alcohol or substance abuse not in remission
- Enrollment in another investigational study within 30 days
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT00686998
Start Date
May 1 2008
End Date
March 1 2009
Last Update
March 29 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Rockville, Maryland, United States